Bleeding Disorders Awareness

Returning guest, Dr. Amy Shapiro, MD, Medical Director and CEO at the Indiana Hemophilia & Thrombosis Center and a member of the National Hemophilia Program Coordinating Center (NHPCC) Steering Committee discusses how they are facing the health challenges faced by the bleeding disorders community as outlined in Healthy People 2030 (HP2030) an initiative that addresses the latest public health priorities.  Despite being rare, bleeding disorders were recently named one of the most pressing public health issues in the U.S., alongside conditions such as cancer, diabetes, and heart disease through HP2030. 

Read More

RxBenefits – Membership Growth Amid Rising Benefits Costs

Nathan White, Chief Client Officer of RxBenefits discusses how data analytics combined with clinical oversights can reduce costs for employers and improve health outcomes for members leveraging the Pharmacy Benefits Optimizer (PBO) model. He talks about the products and technology developments the company has planned for the coming months, the significant milestones that led to the company’s growth, and how its recent recapitalization by Advent International positions them to better address an underserved market in 2021.

Read More

Overcoming Obstacles in Neuroscience at Start of Pandemic

Dr. Dalia Moawad, MD, Executive Director & Disease Area Lead for Neurological Rare Diseases at Genentech discusses the three things her team learned during the pandemic from the launching of Evrysdi (risdiplam) the first at-home oral medicine for adults and children two months of age and older with spinal muscular atrophy (SMA).

Read More

LinQ is a Safe and Minimally Invasive Solution to Treat SI Joint Pain

In up to 30% of people with chronic low back pain, the SI joint is the hidden source of the pain. SI joint pain is often misunderstood and misdiagnosed. Only 10% of people with SI joint pain receive the treatment and relief they need to pursue active and healthy lives. LinQ by PainTEQ is the only minimally invasive solution on the market backed by extensive clinical research that can provide immediate pain relief. This is how LinQ works

Read More

First Patient in Landmark Clinical Study Evaluating Engineered Macrophages in Humans

Carisma Therapeutics, Inc. announced (March 2021) that the first patient has been dosed in the Phase 1 multi-center clinical trial for CT-0508, studying the potential of chimeric antigen receptor macrophages (CAR-Ms) for cancer immunotherapy, specifically in solid tumors.  Dr. Debora Barton, MD, Chief Medical Officer at Carisma is here to talk about this novel approach in gene-based therapy development, as it is the first time CAR–engineered macrophages are being studied in humans. CAR-T cell therapy has revolutionized how cancer is treated and revealed the power of gene-based therapies, and it has met challenges with solid tumors. Carisma’s novel approach to immunotherapy may uncover potential treatment options that aim to address the unmet needs of patients, who are battling hard-to-treat cancers. 

Read More

Regaining Hope After An Overwhelming Year in the Pandemic

Licensed marriage and family therapist and certified grief and trauma counselor, Kara Bowman discusses her new book entitled “Heartbreak to Hope: Poems of Support for Grief and Loss”.  She talks about how the book can help guide people through their experiences of isolation, sadness, and grief. She advises some other ways to find effective methods for dealing with painful emotions and find the capacity to grow, heal, connect and find meaning.

Read More